From design to the clinic: practical guidelines for translating cardiovascular nanomedicine
Abstract Cardiovascular diseases (CVD) account for nearly half of all deaths in Europe and almost 30% of global deaths. Despite the improved clinical management, cardiovascular mortality is predicted to rise in the next decades due to the increasing impact of aging, obesity, and diabetes. The goal o...
Gespeichert in:
| Veröffentlicht in: | Cardiovascular research 2018-11, Vol.114 (13), p.1714-1727 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1727 |
|---|---|
| container_issue | 13 |
| container_start_page | 1714 |
| container_title | Cardiovascular research |
| container_volume | 114 |
| creator | Cicha, Iwona Chauvierre, Cédric Texier, Isabelle Cabella, Claudia Metselaar, Josbert M Szebeni, János Dézsi, László Alexiou, Christoph Rouzet, François Storm, Gert Stroes, Erik Bruce, Donald MacRitchie, Neil Maffia, Pasquale Letourneur, Didier |
| description | Abstract
Cardiovascular diseases (CVD) account for nearly half of all deaths in Europe and almost 30% of global deaths. Despite the improved clinical management, cardiovascular mortality is predicted to rise in the next decades due to the increasing impact of aging, obesity, and diabetes. The goal of emerging cardiovascular nanomedicine is to reduce the burden of CVD using nanoscale medical products and devices. However, the development of novel multicomponent nano-sized products poses multiple technical, ethical, and regulatory challenges, which often obstruct their road to successful approval and use in clinical practice. This review discusses the rational design of nanoparticles, including safety considerations and regulatory issues, and highlights the steps needed to achieve efficient clinical translation of promising nanomedicinal products for cardiovascular applications. |
| doi_str_mv | 10.1093/cvr/cvy219 |
| format | Article |
| fullrecord | <record><control><sourceid>oup_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6198738</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/cvr/cvy219</oup_id><sourcerecordid>10.1093/cvr/cvy219</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-1b281d24a7283d91dad9c939fab3d20efbe29a3f2e259dede39eb163b715b843</originalsourceid><addsrcrecordid>eNp9kU1LAzEQhoMotlYv_gDJxYPCaj72Kx6EUqwKBS-9eQjZJLuNbDdLsrvQf2_KalEPHkIyM8-8GeYF4BKjO4wYvZeDC2dHMDsCU5wlSURJnByDKUIoj1Ka0gk48_4jhEmSxadgQhFO988peF86u4VKe1M1sLOw22goa9MY-QBbJ2RnpKhh1RulQ1Z7WFoHOycaX4vONBWUwiljB-FlXwsHG9HYrVZGBvgcnJSi9vri656B9fJpvXiJVm_Pr4v5KpJxTLoIFyTHisQiIzlVDCuhmGSUlaKgiiBdFpowQUuiScKUVpoyXeCUFhlOijymM_A4yrZ9Eb6Wugnz1bx1Zivcjlth-O9KYza8sgNPMcszmgeBm1Fg86ftZb7i-xwiMc2TmA44sLcjK5313uny0IAR37vBgxt8dCPAVz8nO6Df6w_A9QjYvv1P6BNGXZY-</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>From design to the clinic: practical guidelines for translating cardiovascular nanomedicine</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Cicha, Iwona ; Chauvierre, Cédric ; Texier, Isabelle ; Cabella, Claudia ; Metselaar, Josbert M ; Szebeni, János ; Dézsi, László ; Alexiou, Christoph ; Rouzet, François ; Storm, Gert ; Stroes, Erik ; Bruce, Donald ; MacRitchie, Neil ; Maffia, Pasquale ; Letourneur, Didier</creator><creatorcontrib>Cicha, Iwona ; Chauvierre, Cédric ; Texier, Isabelle ; Cabella, Claudia ; Metselaar, Josbert M ; Szebeni, János ; Dézsi, László ; Alexiou, Christoph ; Rouzet, François ; Storm, Gert ; Stroes, Erik ; Bruce, Donald ; MacRitchie, Neil ; Maffia, Pasquale ; Letourneur, Didier</creatorcontrib><description>Abstract
Cardiovascular diseases (CVD) account for nearly half of all deaths in Europe and almost 30% of global deaths. Despite the improved clinical management, cardiovascular mortality is predicted to rise in the next decades due to the increasing impact of aging, obesity, and diabetes. The goal of emerging cardiovascular nanomedicine is to reduce the burden of CVD using nanoscale medical products and devices. However, the development of novel multicomponent nano-sized products poses multiple technical, ethical, and regulatory challenges, which often obstruct their road to successful approval and use in clinical practice. This review discusses the rational design of nanoparticles, including safety considerations and regulatory issues, and highlights the steps needed to achieve efficient clinical translation of promising nanomedicinal products for cardiovascular applications.</description><identifier>ISSN: 0008-6363</identifier><identifier>EISSN: 1755-3245</identifier><identifier>DOI: 10.1093/cvr/cvy219</identifier><identifier>PMID: 30165574</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Cardiology and cardiovascular system ; Editor's Choice ; Engineering Sciences ; Human health and pathology ; Life Sciences ; Micro and nanotechnologies ; Microelectronics ; Reviews</subject><ispartof>Cardiovascular research, 2018-11, Vol.114 (13), p.1714-1727</ispartof><rights>Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018. For permissions, please email: journals.permissions@oup.com. 2018</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-1b281d24a7283d91dad9c939fab3d20efbe29a3f2e259dede39eb163b715b843</citedby><cites>FETCH-LOGICAL-c442t-1b281d24a7283d91dad9c939fab3d20efbe29a3f2e259dede39eb163b715b843</cites><orcidid>0000-0003-2197-9468</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,1578,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30165574$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-02438543$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Cicha, Iwona</creatorcontrib><creatorcontrib>Chauvierre, Cédric</creatorcontrib><creatorcontrib>Texier, Isabelle</creatorcontrib><creatorcontrib>Cabella, Claudia</creatorcontrib><creatorcontrib>Metselaar, Josbert M</creatorcontrib><creatorcontrib>Szebeni, János</creatorcontrib><creatorcontrib>Dézsi, László</creatorcontrib><creatorcontrib>Alexiou, Christoph</creatorcontrib><creatorcontrib>Rouzet, François</creatorcontrib><creatorcontrib>Storm, Gert</creatorcontrib><creatorcontrib>Stroes, Erik</creatorcontrib><creatorcontrib>Bruce, Donald</creatorcontrib><creatorcontrib>MacRitchie, Neil</creatorcontrib><creatorcontrib>Maffia, Pasquale</creatorcontrib><creatorcontrib>Letourneur, Didier</creatorcontrib><title>From design to the clinic: practical guidelines for translating cardiovascular nanomedicine</title><title>Cardiovascular research</title><addtitle>Cardiovasc Res</addtitle><description>Abstract
Cardiovascular diseases (CVD) account for nearly half of all deaths in Europe and almost 30% of global deaths. Despite the improved clinical management, cardiovascular mortality is predicted to rise in the next decades due to the increasing impact of aging, obesity, and diabetes. The goal of emerging cardiovascular nanomedicine is to reduce the burden of CVD using nanoscale medical products and devices. However, the development of novel multicomponent nano-sized products poses multiple technical, ethical, and regulatory challenges, which often obstruct their road to successful approval and use in clinical practice. This review discusses the rational design of nanoparticles, including safety considerations and regulatory issues, and highlights the steps needed to achieve efficient clinical translation of promising nanomedicinal products for cardiovascular applications.</description><subject>Cardiology and cardiovascular system</subject><subject>Editor's Choice</subject><subject>Engineering Sciences</subject><subject>Human health and pathology</subject><subject>Life Sciences</subject><subject>Micro and nanotechnologies</subject><subject>Microelectronics</subject><subject>Reviews</subject><issn>0008-6363</issn><issn>1755-3245</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kU1LAzEQhoMotlYv_gDJxYPCaj72Kx6EUqwKBS-9eQjZJLuNbDdLsrvQf2_KalEPHkIyM8-8GeYF4BKjO4wYvZeDC2dHMDsCU5wlSURJnByDKUIoj1Ka0gk48_4jhEmSxadgQhFO988peF86u4VKe1M1sLOw22goa9MY-QBbJ2RnpKhh1RulQ1Z7WFoHOycaX4vONBWUwiljB-FlXwsHG9HYrVZGBvgcnJSi9vri656B9fJpvXiJVm_Pr4v5KpJxTLoIFyTHisQiIzlVDCuhmGSUlaKgiiBdFpowQUuiScKUVpoyXeCUFhlOijymM_A4yrZ9Eb6Wugnz1bx1Zivcjlth-O9KYza8sgNPMcszmgeBm1Fg86ftZb7i-xwiMc2TmA44sLcjK5313uny0IAR37vBgxt8dCPAVz8nO6Df6w_A9QjYvv1P6BNGXZY-</recordid><startdate>20181101</startdate><enddate>20181101</enddate><creator>Cicha, Iwona</creator><creator>Chauvierre, Cédric</creator><creator>Texier, Isabelle</creator><creator>Cabella, Claudia</creator><creator>Metselaar, Josbert M</creator><creator>Szebeni, János</creator><creator>Dézsi, László</creator><creator>Alexiou, Christoph</creator><creator>Rouzet, François</creator><creator>Storm, Gert</creator><creator>Stroes, Erik</creator><creator>Bruce, Donald</creator><creator>MacRitchie, Neil</creator><creator>Maffia, Pasquale</creator><creator>Letourneur, Didier</creator><general>Oxford University Press</general><general>Oxford University Press (OUP)</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2197-9468</orcidid></search><sort><creationdate>20181101</creationdate><title>From design to the clinic: practical guidelines for translating cardiovascular nanomedicine</title><author>Cicha, Iwona ; Chauvierre, Cédric ; Texier, Isabelle ; Cabella, Claudia ; Metselaar, Josbert M ; Szebeni, János ; Dézsi, László ; Alexiou, Christoph ; Rouzet, François ; Storm, Gert ; Stroes, Erik ; Bruce, Donald ; MacRitchie, Neil ; Maffia, Pasquale ; Letourneur, Didier</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-1b281d24a7283d91dad9c939fab3d20efbe29a3f2e259dede39eb163b715b843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Cardiology and cardiovascular system</topic><topic>Editor's Choice</topic><topic>Engineering Sciences</topic><topic>Human health and pathology</topic><topic>Life Sciences</topic><topic>Micro and nanotechnologies</topic><topic>Microelectronics</topic><topic>Reviews</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cicha, Iwona</creatorcontrib><creatorcontrib>Chauvierre, Cédric</creatorcontrib><creatorcontrib>Texier, Isabelle</creatorcontrib><creatorcontrib>Cabella, Claudia</creatorcontrib><creatorcontrib>Metselaar, Josbert M</creatorcontrib><creatorcontrib>Szebeni, János</creatorcontrib><creatorcontrib>Dézsi, László</creatorcontrib><creatorcontrib>Alexiou, Christoph</creatorcontrib><creatorcontrib>Rouzet, François</creatorcontrib><creatorcontrib>Storm, Gert</creatorcontrib><creatorcontrib>Stroes, Erik</creatorcontrib><creatorcontrib>Bruce, Donald</creatorcontrib><creatorcontrib>MacRitchie, Neil</creatorcontrib><creatorcontrib>Maffia, Pasquale</creatorcontrib><creatorcontrib>Letourneur, Didier</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cardiovascular research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cicha, Iwona</au><au>Chauvierre, Cédric</au><au>Texier, Isabelle</au><au>Cabella, Claudia</au><au>Metselaar, Josbert M</au><au>Szebeni, János</au><au>Dézsi, László</au><au>Alexiou, Christoph</au><au>Rouzet, François</au><au>Storm, Gert</au><au>Stroes, Erik</au><au>Bruce, Donald</au><au>MacRitchie, Neil</au><au>Maffia, Pasquale</au><au>Letourneur, Didier</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>From design to the clinic: practical guidelines for translating cardiovascular nanomedicine</atitle><jtitle>Cardiovascular research</jtitle><addtitle>Cardiovasc Res</addtitle><date>2018-11-01</date><risdate>2018</risdate><volume>114</volume><issue>13</issue><spage>1714</spage><epage>1727</epage><pages>1714-1727</pages><issn>0008-6363</issn><eissn>1755-3245</eissn><abstract>Abstract
Cardiovascular diseases (CVD) account for nearly half of all deaths in Europe and almost 30% of global deaths. Despite the improved clinical management, cardiovascular mortality is predicted to rise in the next decades due to the increasing impact of aging, obesity, and diabetes. The goal of emerging cardiovascular nanomedicine is to reduce the burden of CVD using nanoscale medical products and devices. However, the development of novel multicomponent nano-sized products poses multiple technical, ethical, and regulatory challenges, which often obstruct their road to successful approval and use in clinical practice. This review discusses the rational design of nanoparticles, including safety considerations and regulatory issues, and highlights the steps needed to achieve efficient clinical translation of promising nanomedicinal products for cardiovascular applications.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>30165574</pmid><doi>10.1093/cvr/cvy219</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0003-2197-9468</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-6363 |
| ispartof | Cardiovascular research, 2018-11, Vol.114 (13), p.1714-1727 |
| issn | 0008-6363 1755-3245 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6198738 |
| source | Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Cardiology and cardiovascular system Editor's Choice Engineering Sciences Human health and pathology Life Sciences Micro and nanotechnologies Microelectronics Reviews |
| title | From design to the clinic: practical guidelines for translating cardiovascular nanomedicine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T02%3A20%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=From%20design%20to%20the%20clinic:%20practical%20guidelines%20for%20translating%20cardiovascular%20nanomedicine&rft.jtitle=Cardiovascular%20research&rft.au=Cicha,%20Iwona&rft.date=2018-11-01&rft.volume=114&rft.issue=13&rft.spage=1714&rft.epage=1727&rft.pages=1714-1727&rft.issn=0008-6363&rft.eissn=1755-3245&rft_id=info:doi/10.1093/cvr/cvy219&rft_dat=%3Coup_pubme%3E10.1093/cvr/cvy219%3C/oup_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/30165574&rft_oup_id=10.1093/cvr/cvy219&rfr_iscdi=true |